The weight-loss drug boom is quietly changing hands. As employer health plans retreat from covering Wegovy and Zepbound, a growing share of American patients is paying cash through manufacturer and retailer programs — and the biggest beneficiaries may prove to be the companies that own the pharmacy counter rather than the ones that make the drug. Employers are dropping GLP-1 coverage in greater numbers, pushing more patients toward direct-to-consumer prescription programs and handing Walmart, Costco, CVS and Amazon a shot at a larger slice of the market.

The pullback is measurable. A Mercer study found employers scaled back GLP-1 weight-loss coverage in 2026, with 6% of employers with 500 or more workers dropping it outright and another 5% planning or actively weighing the same move for 2027. Several regional insurers ended obesity-indication coverage at the start of the year, and HCA Healthcare, one of the country’s largest hospital operators, told employees its GLP-1 benefit was ending after utilization jumped 90% in a single year, steering workers toward manufacturer cash-pay programs instead.

Those programs have gotten aggressive on price. Eli Lilly cut Zepbound to $299 a month for starter doses on LillyDirect, with the next dose step at $399 and higher doses at $449. The better pricing is tied to refilling within 45 days, while Novo Nordisk’s NovoCare runs $199 for introductory months before stepping up to $349, and Costco’s partnership with Sesame prices Wegovy at roughly $349 on top of a paid membership.

For retailers, the appeal is not the margin on the vial. It is the calendar. A patient on maintenance therapy comes back every month, indefinitely, and each visit is a trip into the store. Walmart’s role as the retail pickup point for LillyDirect matters because the customer collecting a prescription has to walk the aisles to reach the pharmacy — creating a recurring relationship that retailers spend billions trying to build. Industry analysts say the tiered refill pricing functions much like a loyalty program, rewarding repeat business while encouraging patients to stay within the same ecosystem.

Amazon has moved on the same logic from a different direction. Its primary care arm, Amazon One Medical, launched a GLP-1 management program folding obesity treatment into routine care, combining virtual and in-person visits with prescription management and pharmacy fulfillment, while the company expands same-day prescription delivery to thousands of cities. Walmart has broadened its Better Care Services platform with nutrition, coaching and weight-management support around the prescriptions its pharmacies already fill. CVS has also integrated GLP-1 prescribing through MinuteClinic, pairing evaluation visits with prescriptions filled at its own pharmacies.

The squeeze falls on independent pharmacies. The race among the major chains to fill the coverage gap could leave smaller operators at a disadvantage because they lack the scale to offset lower prescription margins with grocery, general merchandise, memberships and other higher-margin purchases that often accompany a pharmacy visit.

There is also a second-order effect inside many of the same stores. Research has found GLP-1 users generally spend less on restaurants and takeout while trimming grocery purchases more modestly, prompting retailers to introduce higher-protein and portion-focused food offerings. As patients lose weight, many also refresh their wardrobes, creating additional opportunities in apparel and other retail categories.

The open question is how far the cash-pay market can stretch. Survey data show GLP-1 use continues to climb, but most consumers say they can afford only about $100 a month, well below today’s typical cash prices of roughly $299 to $449. That affordability gap could determine how quickly the market expands.

The winners in the GLP-1 boom may not ultimately be the pharmaceutical companies. As more Americans pay cash instead of relying on employer health plans, retailers are positioning the pharmacy as the start of a broader customer relationship. Every monthly refill becomes another store visit, another opportunity to sell groceries, clothing, health services and everyday essentials. In the next phase of the weight-loss market, the company that owns the refill may end up owning far more than the prescription.

JBizNews Desk | New York

© JBizNews.com All Rights Reserved. Reproduction or distribution without written permission is prohibited.